Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
Amgen is a robust long-term investment due ... One of the most promising Phase 3 candidates is AMGN’s MariTide drug for obesity. Management highlighted progress around this and other drugs ...
What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found ...
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
Amgen expects key drugs like Repatha ... Amgen expects to launch the phase III MARITIME study on MariTide across obesity, obesity-related conditions and type-II diabetes, with the first studies ...
Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a ...
Amgen expects key drugs like Repatha ... Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback